About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT06344650

Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess.

Prospective observational clinical, molecular, translational study aimed at identifying the main determinants and predictive factors of fragility fracture risck in acromegaly patients

Lead sponsor: IRCCS San Raffaele•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Stefano Frara, MD

CONTACT

+390226435136 frara.stefano@hsr.it

Gabriela Felipe, Nurse

CONTACT

+390226435136 felipe.gabriela@hsr.it

Sponsors

Lead Sponsor

IRCCS San Raffaele

Collaborators

Fondazione Policlinico Universitario Campus Bio-Medico
Istituto Auxologico Italiano

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•confirmed diagnosis of acromegaly
•availability to carry out outpatient checks
•ability to provide informed consent

Exclusion Criteria

•Pregnancy
•use of glucocorticoids (except those in use for replacement therapy)
•alcohol abuse
•exacerbation of chronic disease
•serious comorbidities (renal or hepatic failure, heart attack, stroke)
•terminally ill, prolonged immobilization (\>1 week)
•clinically evident fracture within the previous six months
•any other cause of secondary osteoporosis within the last five years
•any prolonged treatment with drugs with documented influence on bone metabolism during the previous 12 months, including treatment with antiresorptive or anabolic compounds for osteoporosis.

Related studies

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

NCT00001595 · Panhypopituitarism, Gigantism/Acromegaly, and more

KETOgenic Diet Therapy in Patients With ACROmegaly

NCT06949891 · Acromegaly Due to Pituitary Adenoma, Ketogenic Diet, and more

Active Not RecruitingPhase 3

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly

NCT04837040 · Acromegaly

Not Yet RecruitingPhase 2

A Study to Evaluate MAR002 for Acromegaly

NCT07641179 · Acromegaly

Not Yet Recruiting

An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT07583563 · Acromegaly

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 22, 2024Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment100

Start dateApr 2023

Last updatedAug 22, 2024

Condition

Locations shown

Andrea Giustina

Milan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 22, 2024Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions